<code id='FA351A76AF'></code><style id='FA351A76AF'></style>
    • <acronym id='FA351A76AF'></acronym>
      <center id='FA351A76AF'><center id='FA351A76AF'><tfoot id='FA351A76AF'></tfoot></center><abbr id='FA351A76AF'><dir id='FA351A76AF'><tfoot id='FA351A76AF'></tfoot><noframes id='FA351A76AF'>

    • <optgroup id='FA351A76AF'><strike id='FA351A76AF'><sup id='FA351A76AF'></sup></strike><code id='FA351A76AF'></code></optgroup>
        1. <b id='FA351A76AF'><label id='FA351A76AF'><select id='FA351A76AF'><dt id='FA351A76AF'><span id='FA351A76AF'></span></dt></select></label></b><u id='FA351A76AF'></u>
          <i id='FA351A76AF'><strike id='FA351A76AF'><tt id='FA351A76AF'><pre id='FA351A76AF'></pre></tt></strike></i>

          Home / entertainment / explore

          explore


          explore

          author:knowledge    Page View:69
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In